Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01162304 · ClinicalTrials.gov registry record · Phase 4
Open-Label Trial Comparing Oxycodone Medications
A Phase 4 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT01162304 is a Phase 4 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 18 participants.
The verdict
NCT01162304, a Phase 4 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
The investigators hypothesize that subjects will have greater pain relief when taking IR-oxycodone compared with ER-oxycodone for several reasons. The ability to take a varying amount of medication at six different points over the course of a day will allow patients to take as much (or as little) medication as they need to control their pain. In addition, the ability to vary the medication doses in this way will give them a greater sense of control, which will also contribute to greater pain relief. Similarly, the investigators predict that patients will show greater benefits with IR-oxycodone on the measures of physical and emotional functioning. Because there is relatively little data on sleep apnea in chronic pain patients (Webster et al., 2008), these assessments are exploratory and not hypothesis-based. Finally, although it is typically thought that the abuse liability of IR-opioid medications is greater than for ER-medications, the data on which this belief are based have not involved systematic studies of patients with chronic pain; the assessments of abuse liability will therefore also be exploratory.
Interventions
- DRUG Extended Release Oxycodone
- DRUG Immediate Release Oxycodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01162304
The ClinicalTrials.gov registry entry for NCT01162304 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Extended Release Oxycodone is the first listed.
NCT01162304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01162304 about?
NCT01162304 is a clinical study titled "Open-Label Trial Comparing Oxycodone Medications". The investigators hypothesize that subjects will have greater pain relief when taking IR-oxycodone compared with ER-oxycodone for several reasons. The ability to take a varying amount of medication at six different points over the course of a day will allow patients to take as much (or as little) me...
What is the current status of trial NCT01162304?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2010-03. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01162304?
The interventions under investigation include: Extended Release Oxycodone (DRUG), Immediate Release Oxycodone (DRUG).
Who is sponsoring clinical trial NCT01162304?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.